Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.
Also called NCT06779630
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT06779630
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Austria, France, Germany, Poland, Switzerland
- Registry status
- Recruiting
Technical summary
Registry record NCT06779630. Allocation not applicable; no masking; primary purpose treatment. Start 2025-07-18 (actual); primary completion 2027-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
- Acronym
- BIOFLOW-48
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System
- Lead sponsor
- Teleflex
- Collaborator
- BIOTRONIK AG (A Teleflex Company)
Record details
- Record id
cardio:ct-nct06779630- Content hash
733b44fc7ca416cf3c9c48269b09c9ad6efb7b133909a8a75f97b6b2244ba66f